Outcomes and Attributes Patients Value When Choosing Glucose-Lowering Medications: A Mixed-Methods Study
Elizabeth H Golembiewski1, Andrea E Garcia Bautista1, Eric Polley2
1Knowledge and Evaluation Research (KER) Unit, Mayo Clinic, Rochester, MN.
Summary
Adults with type 2 diabetes prioritize avoiding blindness, death, and heart issues. They prefer glucose-lowering efficacy, oral medications, and fewer GI side effects for their pharmacotherapy.
Area of Science:
- Endocrinology
- Pharmacology
- Public Health
Background:
- Type 2 diabetes management requires effective pharmacotherapy.
- Patient preferences significantly influence treatment adherence and outcomes.
- Understanding patient priorities is crucial for personalized diabetes care.
Purpose of the Study:
- To identify pharmacotherapy preferences in noninsulin-treated adults with type 2 diabetes.
- To determine the relative importance of health outcomes and medication attributes.
- To inform clinical decision-making and treatment selection.
Main Methods:
- Mixed-methods study involving 40 participants.
- Participants ranked health outcomes and medication attributes.
- Qualitative data collection through contextualization of rankings.
Main Results:
- High-priority health outcomes included blindness (63%), death (60%), heart attack (48%), and heart failure (48%).
- Glucose-lowering efficacy was the most important medication attribute (68%).
- Oral administration (45%) and lack of gastrointestinal side effects (38%) were also key preferences.
Conclusions:
- Patient-centered care for type 2 diabetes should address major health concerns like blindness and cardiovascular events.
- Pharmacotherapy selection should prioritize glucose control, oral administration, and gastrointestinal tolerability.
- Incorporating patient preferences can enhance treatment adherence and management of type 2 diabetes.
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
186
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
186
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
168
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
168
01:15Diabetes: Management and Pharmacotherapy
256
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
256
01:06Oral Hypoglycemic Agents: Glinides
152
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
152
01:17Oral Hypoglycemic Agents: Sulfonylureas
199
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
199
01:23Dipeptidyl Peptidase 4 Inhibitors
180
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
180